Hair Regrowth in Endocrine Therapy Alopecia With Dutasteride Treatment in Women With Estrogen Positive Breast Cancer

    March 2023 in “ JAAD case reports ”
    Celina Dubin, Angela Lamb
    Studysummary This paper outlines that treatments reducing estrogen for estrogen receptor-positive breast cancer, such as SERMs and AIs, significantly improve life expectancy but may lead to alopecia in 15% to 25% of patients.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaadcasereports.org →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer JAMA Dermatology · 2018
    2. Minoxidil for Endocrine Therapy–Induced Alopecia in Women With Breast Cancer—Saint Agatha’s Blessing? JAMA Dermatology · 2018
    3. Long-Term Use of 5α-Reductase Inhibitors and the Risk of Male Breast Cancer Cancer Causes & Control · 2014
    4. The Effectiveness of Finasteride and Dutasteride Used for 3 Years in Women with Androgenetic Alopecia Indian Journal of Dermatology, Venereology and Leprology · 2014
    5. Effective Treatment of Female Androgenic Alopecia with Dutasteride PubMed · 2005
    6. Molecular Mechanisms of Androgenetic Alopecia Experimental Gerontology · 2002